Full Underwriting Kura Oncology ($KURA): The Launch Is Working—So Far. The Frontline Bet Is Not Yet Proven. Kura Oncology’s KOMZIFTI launch is gaining traction, but most of the upside depends on unproven frontline AML data. Hayabusa Research examines the evidence, valuation, risks, catalysts, and falsifiers.
